Eli Lilly Files More Lawsuits at Sellers of Counterfeit Mounjaro, Zepbound
By Dean Seal
Eli Lilly is stepping up its campaign against fake and counterfeit weight-loss drugs with more lawsuits against sellers of unapproved products that market themselves as Mounjaro and Zepbound.
The pharmaceutical company said Thursday that it has filed legal actions against med-spas, wellness centers and other entities that sell products purportedly containing tirzepatide, the antidiabetic medication Eli Lilly sells under the brand names Mounjaro and Zepbound.
Eli Lilly claims the defendants are falsely labeling these products as Mounjaro and Zepbound, or as being the same as those drugs, or as being part of Eli Lilly's clinical trials, or as being approved by the Food and Drug Administration.
The suits follow a similar spate of actions the company filed last fall. Eli Lilly reached a settlement deal last month with Totality Medispa for allegedly telling customers that it was selling FDA-approved Mounjaro and Zepbound.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 20, 2024 11:24 ET (15:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks